Sorafenib
From Wikipedia, the free encyclopedia
Sorafenib
|
|
Systematic (IUPAC) name | |
4-[4-[[4-chloro-3-(trifluoromethyl)phenyl]carbamoylamino] phenoxy]-N-methyl-pyridine-2-carboxamide |
|
Identifiers | |
CAS number | |
ATC code | L01 |
PubChem | |
DrugBank | |
Chemical data | |
Formula | C21H16ClF3N4O3 |
Mol. mass | 464.825 g/mol |
SMILES | search in | ,
Synonyms | Nexavar Sorafenib tosylate |
Pharmacokinetic data | |
Bioavailability | 29-49% |
Protein binding | 99.5% |
Metabolism | Hepatic oxidation and glucuronidation (CYP3A4-mediated) |
Half life | 25–48 hours |
Excretion | Fecal (77%) and renal (19%) |
Therapeutic considerations | |
Licence data |
|
Pregnancy cat. | |
Legal status | |
Routes | Oral |
Sorafenib (rINN), marketed as Nexavar by Bayer, is a drug used for the treatment of advanced renal cell cancer. It is a small molecular inhibitor of Raf kinase, PDGF (platelet-derived growth factor) and VEGF receptor kinase.
Sorafenib was approved by the U.S. Food and Drug Administration (FDA) on December 20, 2005.
[edit] Side effects
Side effects of sorafenib included skin rash, hand-foot skin reactions, diarrhea, and hypertension.
[edit] External links
- Prescribing Information – includes data from the key studies justifying the use of sorafenib for the treatment of kidney cancer (particularly clear cell renal cell carcinoma, which is associated with the von-Hippel-Lindau gene)
- Patient Information from FDA
- Sorafenib in Treating Patients With Soft Tissue Sarcomas